IN B013
Alternative Names: IN-B013Latest Information Update: 30 Apr 2021
Price :
$50 *
At a glance
- Originator HK inno.N
- Class Anti-inflammatories; Irritable bowel syndrome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Inflammatory bowel diseases; Irritable bowel syndrome
Most Recent Events
- 20 Apr 2021 IN B013 is available for licensing as of 20 Apr 2021. http://www.inno-n.com/eng/business/out_licensing.asp
- 20 Apr 2021 Early research in Inflammatory bowel diseases in South Korea (unspecified route), prior to April 2021 (HK inno.N pipeline, April 2021)
- 20 Apr 2021 Early research in Irritable bowel syndrome in South Korea (unspecified route), prior to April 2021 (HK inno.N pipeline, April 2021)